NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

IMUX

Immunic Inc

May 09 • 11:16AM ET

1.03

Dollar change +0.01
Percentage change 0.99	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE IOVA AGEN KPTI ADAP MCRB AFMD IMTX ALDX ZLAB

| Held by: VTI VXF IWC QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.03	Insider Own	3.02%	Shs Outstand	95.82M	Perf Week	-10.43%
Market Cap	98.70M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	3.11%	Shs Float	92.92M	Perf Month	11.41%
Income	-100.51M	PEG	-	EPS next Q	-0.24	Inst Own	51.76%	Short Float	2.23%	Perf Quarter	7.22%
Sales	0.00M	P/S	-	EPS this Y	21.00%	Inst Trans	-17.12%	Short Ratio	2.21	Perf Half Y	-13.44%
Book/sh	0.20	P/B	5.04	EPS next Y	8.10%	ROA	-211.22%	Short Interest	2.07M	Perf Year	-25.36%
Cash/sh	0.37	P/C	2.77	EPS next 5Y	-	ROE	-424.44%	52W Range	0.83 - 2.11	Perf YTD	3.01%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.01%	ROI	-537.67%	52W High	-51.18%	Beta	1.64
Dividend TTM	-	Quick Ratio	1.77	Sales past 5Y	0.00%	Gross Margin	-	52W Low	23.82%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	1.77	EPS Y/Y TTM	51.02%	Oper. Margin	-	RSI (14)	47.83	Volatility	9.78% 11.48%
Employees	91	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	13.69
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	42.23%	Payout	-	Rel Volume	1.34	Prev Close	1.02
Sales Surprise	-	EPS Surprise	-4.55%	Sales Q/Q	-	Earnings	Feb 20	Avg Volume	937.78K	Price	1.03
SMA20	-1.91%	SMA50	-5.23%	SMA200	-15.73%	Trades		Volume	387,682	Change	0.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Initiated	William Blair	Outperform
Nov-25-24	Initiated	H.C. Wainwright	Buy	$10
Sep-09-24	Resumed	Leerink Partners	Outperform	$5
Aug-27-24	Initiated	B. Riley Securities	Buy	$6
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$5
Sep-19-22	Resumed	H.C. Wainwright	Buy	$26
Apr-15-21	Initiated	Aegis Capital	Buy	$55
Mar-24-21	Initiated	JMP Securities	Mkt Outperform	$55
Oct-02-20	Initiated	SVB Leerink	Outperform	$45
Aug-26-20	Initiated	Piper Sandler	Overweight	$71
Aug-07-20	Resumed	ROTH Capital	Buy	$64
Jul-20-20	Initiated	BMO Capital Markets	Outperform	$40
Jun-05-20	Initiated	Wedbush	Outperform	$59
May-11-20	Initiated	H.C. Wainwright	Buy	$45
Mar-25-20	Initiated	ROTH Capital	Buy	$44
Jul-11-19	Initiated	Chardan Capital Markets	Buy	$40

Show Previous Ratings

May-02-25 06:30AM	Immunic to Participate in Scientific and Industry Conferences in May (PR Newswire)
May-01-25 01:56PM	Immunic presses ahead with MS drug despite Phase II endpoint miss (Clinical Trials Arena) +18.17%
Apr-30-25 07:30AM	Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (PR Newswire) -22.65%
Apr-28-25 02:09AM	Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (Seeking Alpha)
Apr-10-25 01:00PM	Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
08:10AM	Loading…
Apr-09-25 08:10AM	Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (PR Newswire)
Apr-01-25 06:30AM	Immunic, Inc. to Participate in Scientific and Industry Conferences in April (PR Newswire)
Mar-03-25 06:30AM	Immunic to Participate in Scientific and Investor Conferences in March (PR Newswire)
Feb-26-25 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (PR Newswire)
Feb-20-25 07:30AM	Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (PR Newswire) +12.38%
Feb-04-25 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-07-25 06:30AM	Immunic Highlights 2024 Accomplishments and Upcoming Milestones (PR Newswire)
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire) -9.29%
Nov-26-24 06:30AM	Immunic, Inc. to Participate in Investor Conference in December (PR Newswire)
Nov-14-24 06:35AM	Immunic announces publication of IMU-856 data (TipRanks) -6.84%
06:30AM	Loading…
Nov-13-24 06:30AM	Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (PR Newswire)
Nov-09-24 08:00AM	Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges (GuruFocus.com)
Nov-07-24 06:41AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Oct-31-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (PR Newswire)
Oct-29-24 06:30AM	Immunic to Participate in Industry, Scientific and Investor Conferences in November (PR Newswire)
Oct-22-24 06:30AM	Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (PR Newswire) -9.68%
Oct-09-24 05:31PM	Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... (GuruFocus.com) -6.67%
Sep-18-24 06:30AM	Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (PR Newswire) +11.18%
Sep-04-24 06:30AM	Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (PR Newswire)
Aug-28-24 06:30AM	Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (PR Newswire)
Aug-08-24 06:34AM	Immunic: Q2 Earnings Snapshot (Associated Press Finance) +14.53%
06:30AM	Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (PR Newswire)
Jul-24-24 06:30AM	Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (PR Newswire) -5.48%
06:30AM	Loading…
Jul-09-24 06:30AM	Immunic Appoints Jason Tardio as Chief Operating Officer and President (PR Newswire) +7.76%
May-30-24 07:03AM	Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day (News Direct)
May-28-24 06:30AM	Immunic to Participate in Industry and Scientific Conferences in June (PR Newswire)
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace)
May-20-24 10:00AM	Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day (News Direct)
May-17-24 02:35PM	Immunic chief medical officer discusses promising treatments to mark World IBD Day (News Direct)
May-16-24 05:54PM	Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day (News Direct)
May-09-24 10:23AM	Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:58AM	Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones (News Direct)
May-08-24 06:36AM	Immunic: Q1 Earnings Snapshot (Associated Press Finance) -7.97%
06:30AM	Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
May-06-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in May (PR Newswire)
May-01-24 10:02AM	Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal (News Direct)
06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update (PR Newswire)
Apr-30-24 06:30AM	Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology & Neuroinflammation (PR Newswire)
Apr-29-24 11:11AM	Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role (News Direct)
Apr-04-24 06:30AM	Immunic to Host MS R&D Day and Participate in Investor Conferences in April (PR Newswire)
Mar-21-24 12:14PM	Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month (News Direct)
11:37AM	Immunic secures key patent, boosting MS drug exclusivity and global IP strategy (News Direct)
Mar-20-24 06:30AM	Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States (PR Newswire)
Mar-08-24 06:53AM	Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024 (News Direct)
Mar-07-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in March (PR Newswire)
Feb-29-24 06:30AM	Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 (PR Newswire)
Feb-23-24 09:02PM	Immunic Inc (IMUX) Reports Year-End 2023 Financial Results (GuruFocus.com)
11:04AM	Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:59AM	Immunic reports successful 2023 and prepares for key 2025 milestones (News Direct)
06:30AM	Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire)
Feb-15-24 06:30AM	Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update (PR Newswire)
Feb-01-24 06:30AM	Immunic to Participate in Investor and Scientific Conferences in February (PR Newswire)
Jan-05-24 06:35AM	Immunic Highlights 2023 Accomplishments and Upcoming Milestones (PR Newswire)
06:30AM	Immunic, Inc. Announces Private Placement of up to $240 Million (PR Newswire)
Nov-21-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis (PR Newswire)
Nov-14-23 01:25PM	Immunic focusing on business development during Q4 (News Direct)
06:36AM	Immunic: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 06:30AM	Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update (PR Newswire)
Nov-02-23 06:30AM	Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts (PR Newswire)
Oct-26-23 06:30AM	Immunic to Participate in Scientific and Industry Conferences in November (PR Newswire)
Oct-24-23 07:51AM	Immunic CSO hails "great" progress with MS program (News Direct)
Oct-16-23 06:30AM	Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-15-23 06:30AM	Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 (PR Newswire)
Oct-11-23 06:30AM	Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting (PR Newswire)
05:15AM	Immunic "super excited" about latest PMS trial data (News Direct)
Oct-10-23 09:07AM	Immunic's investors appeased by interim biomarker data from phase 2 MS trial (FierceBiotech.com) -13.84%
Oct-09-23 04:01PM	Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Oct-04-23 06:30AM	Immunic to Participate in Scientific Conferences in October (PR Newswire)
Sep-06-23 06:30AM	Immunic to Participate in Industry and Investor Conferences in September (PR Newswire)
Aug-21-23 08:00AM	Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment (News Direct)
Aug-17-23 06:30AM	Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis (PR Newswire)
Aug-07-23 09:50AM	Immunic CEO says Q2 results "couldn't be better" (News Direct) -5.97%
Aug-03-23 06:47AM	Immunic: Q2 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-01-23 06:30AM	Immunic to Participate in Investor and Scientific Conferences in August (PR Newswire)
Jul-28-23 04:19PM	10 Best Rated Penny Stocks to Buy According to Analysts (Insider Monkey) +16.18%
Jul-27-23 06:30AM	Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update (PR Newswire) -6.42%
Jul-25-23 08:00AM	Immunic Inc eyeing "big step" for multiple sclerosis patients (News Direct)
Jul-24-23 10:33AM	With 50% stake, Immunic, Inc. (NASDAQ:IMUX) seems to have captured institutional investors' interest (Simply Wall St.)
Jun-29-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in July (PR Newswire) +18.56%
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +11.89%
09:11AM	Pleasing Signs As A Number Of Insiders Buy Immunic Stock (Simply Wall St.)
Jun-26-23 03:44PM	Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases (News Direct)
May-31-23 07:42AM	Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis (News Direct) -5.17%
May-30-23 06:30AM	Immunic to Participate in Scientific and Investor Conferences in June (PR Newswire)
May-17-23 10:00AM	Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program (News Direct) +6.47%
06:30AM	Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis (PR Newswire)
May-16-23 01:07PM	Immunic Inc set to bring relief with encouraging results (News Direct)
May-11-23 06:40AM	Immunic: Q1 Earnings Snapshot (AP Finance)
06:30AM	Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-09-23 06:30AM	Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update (PR Newswire)
May-06-23 06:30AM	Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action (PR Newswire)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm's products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rudick Richard Alan	Director	Nov 12 '24	Buy	1.15	87,300	100,369	87,300	Nov 13 02:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMUX

Immunic Inc

Upgrade your FINVIZ experience